403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Why Did UPB Stock Pop 20% In Pre-Market Today?
(MENAFN- AsiaNet News)
Shares of Upstream Bio Inc. (UPB) surged nearly 20% in pre-market trading on Wednesday after the company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.
Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function.
Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment's durability.
Read updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment